Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06018116 2024-02-15

CANUCK-01

Phase 2 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1 Completed

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT00482807 2023-11-24

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1 Completed

9 enrolled

Genitourinary

Prostatic Neoplasms

NCT00541047 2023-11-13

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

Phase 3 Completed

4,236 enrolled

GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

NCT00651326 2023-08-04

DART

Phase 3 Terminated

48 enrolled

Genitourinary

Prostatic Neoplasms

NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Phase 2 Completed

60 enrolled

Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

NCT00771017 2023-05-25

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02058706 2023-05-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 2 Completed

71 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT05019846 2023-04-18

SPA

Phase 3 Recruiting

310 enrolled

Genitourinary

Prostatic Neoplasms

NCT03043807 2023-02-16

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2 Completed

26 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT00055731 2023-01-18

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase 3 Completed

413 enrolled

Genitourinary

Prostatic Neoplasms

NCT00004124 2022-12-30

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Phase 3 Completed

983 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT03971110 2022-12-16

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Phase 4 Terminated

9 enrolled

Genitourinary

Advanced Prostate Cancer

Clinical Trials

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

VA STARPORT

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

ARCH

BiolenRT

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

ARPEGGIO

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

S1216

STEEL

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

BicaBCa

INTREPId (INTermediate Risk Erection PreservatIon Trial)

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Drugs-SNPs

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

PCS III

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

CANUCK-01

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

DART

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

SPA

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.